Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ABVC BioPharma, Inc. - Common Stock (NQ: ABVC )

0.4565 +0.0375 (+8.95%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 238,939
Open 0.4100
Bid (Size) 0.4250 (10)
Ask (Size) 0.4360 (1)
Prev. Close 0.4190
Today's Range 0.4100 - 0.4600
52wk Range 0.4000 - 1.730
Shares Outstanding 24,420,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion
FREMONT, CA - February 12, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focusing on innovative treatments in ophthalmology, CNS (central nervous... 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-28.82%
-28.82%
1 Month
-17.17%
-17.17%
3 Month
-10.56%
-10.56%
6 Month
-34.33%
-34.33%
1 Year
-64.06%
-64.06%

More News

Read More
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Via NewMediaWire
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees
Via TheNewswire.com
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024
Via InvestorPlace
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024
Via InvestorPlace
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Via TheNewswire.com
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market
Via NewMediaWire
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market
Via TheNewswire.com
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees
Via NewMediaWire
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement
Via NewMediaWire
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement
Via TheNewswire.com
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
Via NewMediaWire
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
Via NewMediaWire
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
Via TheNewswire.com
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
Via NewMediaWire
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
Via NewMediaWire
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
Via NewMediaWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.